Also I'd like to get the board's thoughts on whether anyone knows whether Daxas is effective at managing COPD? Apparently FRX changed their NDA from "a broad maintenance treatment of copd" to a more narrowly focused "reduction in copd exacerbations"... Does anyone know if this is FRX saying that daxas (roflumilast) is ineffective at managing COPD? If not, then why would FRX make the indication change? Apparently the FDA advisory panel is saying that they're not going to review this more narrow indication at Wednesday's meeting, because it was too late for FRX to make the change.
Would it be worth selling FRX today then maybe buying back in on Thursday?
Anyone have any thoughts on today's new information?
The advisory board is still reviewing roflumilast on wednesday, but they are not reviewing it for the more narrow indication requested by FRX. I'm trying to get a feel for whether this more narrow indication is as big a market as the original full COPD market or if this more narrow indication is a much, much smaller market?
Hopefully only folks with intelligent, inciteful thougths/information who have thoroughly read the post will reply.